Table of Contents
<< Previous Issue | Jul 2016 (Vol: 2016, Issue: 7) | Next Issue >> |
- Section: Licensing
-
Novartis bolsters its immuno-oncology pipeline with Xencor’s bispecific antibodies
-
Takeda Bolsters Gastrointestinal Franchise with Acquisition of Ex-US Rights to Cx601
- Section: Mergers & Acquisitions
-
Struggling Aegerion and QLT Seek Fresh Start via Merger
-
BMS Acquires Cormorant to Expand Immuno-oncology Pipeline
-
Juno Turns to Immuno-Oncology Combinations with Acquisition of RedoxTherapies
- Section: Research & Development
-
Merck & Co Extend Association with Moderna on New Oncology Programme